Genetic Factors Related to Aspirin Resistance Using the Multiplate® Device in Hong Kong Chinese Patients with Stable Coronary Heart Disease

Overview

Journal Heliyon

Specialty Social Sciences

Date 2024 Aug 8

PMID 39113978

Authors

Weiwei Zeng

Tanya Tw Chu

Elaine Yk Chow

Miao Hu

Benny Sp Fok

Juliana Cn Chan

Bryan Py Yan

Brian Tomlinson

Affiliations

Soon will be listed here.

Abstract

Objective: Associations between single nucleotide polymorphisms (SNPs) and aspirin resistance (AR) have been studied with variable results. The associations of genetic variants with AR may be helpful to explain why some individuals demonstrate aspirin insensitivity with this anti-platelet therapy. The purpose of this research was to investigate the effect of different genotypes in candidate genes on aspirin response in patients taking long-term aspirin therapy by measuring the serum thromboxane B2 (TXB2) and platelet function using the Multiplate® analyser.

Methods: A total of 266 patients with stable coronary heart disease (CHD) taking low-dose aspirin for long periods of time and without any other anti-platelet drugs medications were enrolled into the study. They were required to take 80 mg of aspirin every morning for a week including the day before blood tests. Blood samples were collected 24 h after the last dose. The 80 mg dose of aspirin was taken orally and blood samples were collected again 1 h later. The serum TXB2 levels were measured in samples at 24 h post-dose and 1 h post-dose using the EIA kit and platelet activity was determined using the Multiplate® Impedance Platelet Aggregometry (ASPI) assay. Genotyping assays were performed by the TaqMan SNP genotyping technique.

Results: Of the 266 patients, only 251 patients were enrolled in the present study. The -1676 A G (rs1330344) and the -765 G C (rs20417) SNPs showed significant associations with the ASPI measurements in samples taken at 24 h post-dose, but not with the values at 1 h post-dose or with the TXB2 levels ( < 0.05).

Conclusions: Our results suggest that polymorphisms in the and the genes may be associated with reduced anti-aggregatory effects and increased the risk of AR, but future larger-scale cohort studies are necessary for further validation.

Citing Articles

Assessment of Platelet Response to Aspirin Therapy and Hemocompatibility-Related Adverse Events in HeartMate 3 Left Ventricular Assist Device Recipients.

Al Asadi H, Abart T, Schwarz C, Moayedifar R, Schaefer A, Marko C J Clin Med. 2024; 13(23).

PMID: 39685693 PMC: 11642010. DOI: 10.3390/jcm13237234.

References

Xu Z, Jiao J, Yang R, Luo B, Wang X, Wu F . Aspirin resistance: clinical significance and genetic polymorphism. J Int Med Res. 2012; 40(1):282-92. DOI: 10.1177/147323001204000128. View

Yi X, Wang C, Zhou Q, Lin J . Interaction among COX-2, P2Y1 and GPIIIa gene variants is associated with aspirin resistance and early neurological deterioration in Chinese stroke patients. BMC Neurol. 2017; 17(1):4. PMC: 5223580. DOI: 10.1186/s12883-016-0788-8. View

Brun C, Daali Y, Combescure C, Zufferey A, Michelson A, Fontana P . Aspirin response: Differences in serum thromboxane B2 levels between clinical studies. Platelets. 2015; 27(3):196-202. DOI: 10.3109/09537104.2015.1072147. View

Xu K, Ye S, Zhang S, Yang M, Zhu T, Kong D . Impact of Platelet Endothelial Aggregation Receptor-1 Genotypes on Platelet Reactivity and Early Cardiovascular Outcomes in Patients Undergoing Percutaneous Coronary Intervention and Treated With Aspirin and Clopidogrel. Circ Cardiovasc Interv. 2019; 12(5):e007019. DOI: 10.1161/CIRCINTERVENTIONS.118.007019. View

Yang J, Chen X, Zhou J, Hu S, Tang Y . Associations of candidate gene polymorphisms with poor responsiveness to aspirin: a meta-analysis. Clin Exp Pharmacol Physiol. 2018; . DOI: 10.1111/1440-1681.12973. View

Peng L, Zhao Y, Zhou Z, Jin J, Zhao M, Chen X . Associations of MDR1, TBXA2R, PLA2G7, and PEAR1 genetic polymorphisms with the platelet activity in Chinese ischemic stroke patients receiving aspirin therapy. Acta Pharmacol Sin. 2016; 37(11):1442-1448. PMC: 5099418. DOI: 10.1038/aps.2016.90. View

Patrono C, Rocca B . Measurement of Thromboxane Biosynthesis in Health and Disease. Front Pharmacol. 2019; 10:1244. PMC: 6832017. DOI: 10.3389/fphar.2019.01244. View

Lewis J, Riaz M, Xie S, Polekhina G, Wolfe R, Nelson M . Genetic Variation in PEAR1, Cardiovascular Outcomes and Effects of Aspirin in a Healthy Elderly Population. Clin Pharmacol Ther. 2020; 108(6):1289-1298. PMC: 7959328. DOI: 10.1002/cpt.1959. View

Xu Y, Wang Y, Yan S, Zhou Y, Yang Q, Pan Y . Intracellular adenosine regulates epigenetic programming in endothelial cells to promote angiogenesis. EMBO Mol Med. 2017; 9(9):1263-1278. PMC: 5582416. DOI: 10.15252/emmm.201607066. View

10.

Du G, Lin Q, Wang J . A brief review on the mechanisms of aspirin resistance. Int J Cardiol. 2016; 220:21-6. DOI: 10.1016/j.ijcard.2016.06.104. View

11.

Kidson-Gerber G, Weaver J, Gemmell R, Prasan A, Chong B . Serum thromboxane B2 compared to five other platelet function tests for the evaluation of aspirin effect in stable cardiovascular disease. Heart Lung Circ. 2010; 19(4):234-42. DOI: 10.1016/j.hlc.2009.11.002. View

12.

Cao L, Zhang Z, Sun W, Bai W, Sun W, Zhang Y . Impacts of COX-1 gene polymorphisms on vascular outcomes in patients with ischemic stroke and treated with aspirin. Gene. 2014; 546(2):172-6. DOI: 10.1016/j.gene.2014.06.023. View

13.

Hall K, Kessler T, Buring J, Passow D, Sesso H, Zee R . Genetic variation at the coronary artery disease risk locus GUCY1A3 modifies cardiovascular disease prevention effects of aspirin. Eur Heart J. 2019; 40(41):3385-3392. PMC: 6933533. DOI: 10.1093/eurheartj/ehz384. View

14.

Morton M, Kubiak-Balcerewicz K, Sarnowska A, Fiszer U . Biochemical aspirin resistance in acute stroke patients and its association with clinical factors: a prospective pilot study. Folia Neuropathol. 2021; 59(3):271-275. DOI: 10.5114/fn.2021.109434. View

15.

Guirguis-Blake J, Evans C, Perdue L, Bean S, Senger C . Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2022; 327(16):1585-1597. DOI: 10.1001/jama.2022.3337. View

16.

Yi X, Cheng W, Lin J, Zhou Q, Wang C . Interaction between COX-1 and COX-2 Variants Associated with Aspirin Resistance in Chinese Stroke Patients. J Stroke Cerebrovasc Dis. 2016; 25(9):2136-44. DOI: 10.1016/j.jstrokecerebrovasdis.2016.05.039. View

17.

Weng Z, Li X, Li Y, Lin J, Peng F, Niu W . The association of four common polymorphisms from four candidate genes (COX-1, COX-2, ITGA2B, ITGA2) with aspirin insensitivity: a meta-analysis. PLoS One. 2013; 8(11):e78093. PMC: 3828324. DOI: 10.1371/journal.pone.0078093. View

18.

Xiang Q, Zhou S, Lewis J, Shuldiner A, Ren G, Cui Y . Genetic Variants of PEAR1 are Associated with Platelet Function and Antiplatelet Drug Efficacy: A Systematic Review and Meta-Analysis. Curr Pharm Des. 2017; 23(44):6815-6827. DOI: 10.2174/1381612823666170817122043. View

19.

Bellenguez C, Bevan S, Gschwendtner A, Spencer C, Burgess A, Pirinen M . Genome-wide association study identifies a variant in HDAC9 associated with large vessel ischemic stroke. Nat Genet. 2012; 44(3):328-33. PMC: 3303115. DOI: 10.1038/ng.1081. View

20.

Godley R, Hernandez-Vila E . Aspirin for Primary and Secondary Prevention of Cardiovascular Disease. Tex Heart Inst J. 2016; 43(4):318-9. PMC: 4979389. DOI: 10.14503/THIJ-16-5807. View